Potent agonists of the Hedgehog signaling pathway

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 15, 2009, Pages 4308-4311

  Brunton, Shirley A ^a   Stibbard, John H A ^a   Rubin, Lee L ^b   Guicherit, Oivin M ^b   Kruse, Lawrence I ^b   Price, Stephen ^a   di Lucrezia, Raffaella ^a   MacKinnon, Colin H ^a   Avery, Alaric ^a   Park, Yvonne ^a   Buxton, Danielle ^a   Boyd, Edward A ^a  

^a EVOTEC UK LTD   (United Kingdom)

^b CURIS INC   (United States)

Author keywords

Agonist; Hedgehog signaling pathway; SAR study; Small molecule

Indexed keywords

1,4 DIAMINOCYCLOHEXANE; AMIDE; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ADMINISTRATION, ORAL; ANIMALS; CARBOXYLIC ACIDS; CELL LINE; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; HEDGEHOG PROTEINS; HUMANS; MICE; MODELS, BIOLOGICAL; MODELS, CHEMICAL; STROKE; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES;

ERINACEIDAE;

EID: 67649981132     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.05.096     Document Type: Article

References (16)

1. Chiang C., Litingtung Y., Lee E., Young K.E., Corden J.L., Westphal H., and Beachy P.A. Nature 383 (1996) 407
2. St.-Jacques B., Hammerschmidt M., and McMahon A.P. Genes Dev. 13 (1999) 2072
3. Ingham P.W., and McMahon A.P. Genes Dev. 15 (2001) 3059
4. Kusano K.F., Allendoerfer K.L., Munger W., Pola R., Bosch-Marce M., Kirchmair R., Yoon Y., Curry C., Silver M., Kearney M., Asahara T., and Losordo D.W. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 2102
5. Mahindroo, N.; Punchihewa, C.; Fujii. J. Med. Chem. doi:10.1021/jm801420y and references cited therein.
6. Wu X., Walker J., Zhang J., Ding S., and Schultz P.G. Chem. Biol. 11 (2004) 1229
7. Frank-Kamenetsky M., Zhang X.M., Bottega S., Guicherit O., Wichterle H., Dudek H., Bumcrot D., Wang F.Y., Jones S., Shulok J., Rubin L.L., and Porter J.S. J. Biol. 1 (2002) 10
8. max, the maximal response relative to the Hh protein control was determined for selected compounds. For a more detailed description of the GLi-luc assay see:. Brunton S.A., Stibbard J.H.A., Rubin L.L., Kruse L.I., Guicherit O.M., Boyd E.A., and Price S. J. Med. Chem. 51 (2008) 1108
9. Carey F.A. Organic Chemistry (1996), McGraw-Hill 901
10. Reid W., Oremek G., and Ocakcioglu B. Liebigs Ann. Chem. 9 (1980) 1424
11. Shirley D.A., Danzig M.J., and Canter F.C. J. Am. Chem. Soc. 75 (1953) 3278
12. Schneller S.W., Clough F.W., and Hardee L.E.J. Heteroat. Chem. 13 (1976) 273
13. Eicher T., Fey S., Puhl W., Buechel E., and Speicher A. Eur. J. Org. Chem. 5 (1998) 877
14. Prepared by N-methylation of the mono-Boc diamine. Synthesis of that intermediate is described by:. Ducruet A.P., Rice R.L., Tamura K., Yokokawa F., Yokokwara S., Wipf P., and Lazo J.S. Bioorg. Med. Chem. 8 (2000) 1451
15. A member of this class of compounds was shown to activate Shh signaling using a primary astrocyte model. See:. Atkinson P.J., Dellovade T., Albers D., Von Schack D., Saraf K., Needle E., Reinhart P.H., and Hirst W. J. Neurochem. 108 (2009) 1539
16. Compound 21K showed a high volume of distribution (Vss = 23.4 L/kg at 3 mg/kg iv in rats) and the compound was detected in skin (data not shown).